News

The lawsuit seeks to stop Vi-Jon from violating P&G’s intellectual property and selling the infringing products. The lawsuit alleges that Vi-Jon is violating P&G’s intellectual property by manufacturing

SPRIX, which uses an Aptar Pharma nasal spray pump, is a non-invasive treatment for pain management. Aptar Pharma worked closely with Roxro Pharma for over 7 years to

Krystexxa is indicated as a treatment for chronic gout in adult patients refractory to conventional therapy. The MAA was submitted on the basis of safety and efficacy data

TheraPEG technology is used for the site-specific attachment of polyethylene glycol (PEG) polymer to therapeutic proteins. TheraPEG offers site-specific conjugation to disulfide bonds to achieve better product homogeneity

Following the acquisition, Aegera’s 20 plus employees will be joining Pharmascience’s team. The acquisition will allow Pharmascience to enhance its research and development activities through the continuance of

The dual site, two-cohort, open-label clinical trial is intended to assess the safety, bioactivity and anti tumor effect of infusion of patients’ own T cells that have been

The study aims to investigate the safety and tolerability of the treatment in progressive doses while assessing longer term efficacy measures for the design of future clinical trials

The rebranding of the firm is subject to approval of the Registrar of companies in India. Mylan expects to keep the Matrix name for the institutional ARV franchise,

NaAPR1M-74 is expected to be investigated as a potential vaccine candidate for human hookworm disease. The production is resulted from the collaboration between iBio’s research partner, the Fraunhofer